Factors affecting serum concentrations of hepatitis C virus (HCV) RNA in HCV genotype 1-infected patients with chronic hepatitis

Journal of Clinical Microbiology

Volumn 45, Issue 8, 2007, Pages 2426-2433

  Ticehurst, John R ^a,b,c   Hamzeh, Fayez M ^d   Thomas, David L ^b,c  

^a JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS RNA;

ADULT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY MASS; BODY WEIGHT; CHRONIC HEPATITIS; FEMALE; GENDER; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER FIBROSIS; LIVER NECROSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; PRIORITY JOURNAL; RACE; SERUM;

ADOLESCENT; ADULT; AGE FACTORS; AGED; BODY MASS INDEX; BODY WEIGHT; FEMALE; HEPACIVIRUS; HEPATITIS, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS; RISK FACTORS; RNA, VIRAL; SEX FACTORS; VIRAL LOAD;

HEPATITIS C VIRUS;

EID: 34548081220     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.02448-06     Document Type: Article

References (72)

1. Arase, Y., K. Ikeda, K. Chayama, N. Murashima, A. Tsubota, Y. Suzuki, S. Saitoh, M. Kobayashi, F. Suzuki, and H. Kumada. 2000. Fluctuation patterns of HCV-RNA serum level in patients with chronic hepatitis C. J. Gastroenterol. 35:221-225.
2. Bressler, B. L., M. Guindi, G. Tomlinson, and J. Heathcote. 2003. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 38:639-644.
3. Bukh, J., R. H. Miller, and R. H. Purcell. 1995. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin. Liver Dis. 15:41-63.
4. Chen, Z., and K. E. Week. 2002. Hepatitis C virus genotyping: interrogation of the 5′ untranslated region cannot accurately distinguish genotypes 1a and 1b. J. Clin. Microbiol. 40:3127-3134.
5. Corbet, S., J. Bukh, A. Heinsen, and A. Fomsgaard. 2003. Hepatitis C virus subtyping by a core-envelope 1-based reverse transcriptase PCR assay with sequencing and its use in determining subtype distribution among Danish patients. J. Clin. Microbiol. 41:1091-1100.
6. Davidson, F., P. Simmonds, J. C. Ferguson, L. M. Jarvis, B. C. Dow, E. A. Follett, C. R. Seed, T. Krusius, C. Lin, and G. A. Medgyesi. 1995. Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5' non-coding region. J. Gen. Virol. 76:1197-1204.
7. Davis, G. L., R. Esteban-Mur, V. Rustgi, J. Hoefs, S. C. Gordon, C. Trepo, M, L. Shiffman, S. Zeuzem, A. Craxi, M. H. Ling, J. Albrecht, and the International Hepatitis Interventional Therapy Group. 1998. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N. Engl. J. Med. 339:1493-1499.
8. Dufour, D. R., J. A. Lott, F. S. Nolte, D. R. Gretch, R. S. Koff, and L. B. Seeff. 2000. Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests. Clin. Chem. 46:2027-2049.
9. Dufour, D. R., J. A. Lott, F. S. Nolte, D. R. Gretch, R. S. Koff, and L. B. Seeff. 2000. Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. Clin. Chem. 46:2050-2068.
10. Edwards-Smith, C. J., J. R. Jonsson, D. M. Purdie, A. Bansal, C. Shorthouse, and E. E. Powell. 1999. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology 30:526-530.
11. Eyster, M. E., M. W. Fried, A. M. Di Bisceglie, and J. J. Goedert. 1994. Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study. Blood 84:1020-1023.
12. Fanning, L., E. Kenny-Walsh, J. Levis, K. R. Choudhury, B. Cannon, M. Sheehan, M. Whelton, and F. Shanahan. 2000. Natural fluctuations of hepatitis C viral load in a homogeneous patient population: a prospective study. Hepatology 31:225-229.
13. Farci, P., H. J. Alter, D. Wong, R. H. Miller, J. W. Shih, B. Jett, and R. H. Purcell. 1991. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N. Engl. J. Med. 325:98-104.
14. Ferreira-Gonzalez, A., and M. L. Shiffman. 2004. Use of diagnostic testing for managing hepatitis C virus infection. Semin. Liver Dis. 24:9-18.
15. Fleckenstein, J. 2004. Chronic hepatitis C in African Americans and other minority groups. Curr. Gastroenterol. Rep. 6:66-70.
16. Fried, M. W., M. L. Shiffman, K. R. Reddy, C. Smith, G. Marinos, F. L. Goncales, Jr., D. Haussinger, M. Diago, G. Carosi, D. Dhumeaux, A. Craxi, A. Lin, J. Hoffman, and J. Yu. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347:975-982.
17. Germer, J. J., P. N. Rys, J. N. Thorvilson, and D. H. Persing. 1999. Determination of hepatitis C virus genotype by direct sequence analysis of products generated with the Amplicor HCV test. J. Clin. Microbiol. 37:2625-2630.
18. Gordon, S. C., P. J. Dailey, A. L. Silverman, B. A. Khan, V. P. Kodali, and J. C. Wilber. 1998. Sequential serum hepatitis C viral RNA levels longitudinally assessed by branched DNA signal amplification. Hepatology 28:1702-1706.
19. Gretch, D., L. Corey, J. Wilson, C. de la Rosa, R. Willson, R. Carithers, Jr., M. Busch, J. Hart, M. Sayers, and J. Han. 1994. Assessment of hepatitis C virus RNA levels by quantitative competitive RNA polymerase chain reaction: high-titer viremia correlates with advanced stage of disease. J. Infect. Dis. 169:1219-1225.
20. Hadziyannis, S. J., H. Sette, Jr., T. R. Morgan, V. Balan, M. Diago, P. Marcellin, G. Ramadori, H. Bodenheimer, Jr., D. Bernstein, M. Rizzetto, S. Zeuzem, P. J. Pockros, A. Lin, and A. M. Ackrill for the PEGASYS International Study Group. 2004. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 140:346-355.
21. Hagiwara, H., N. Hayashi, E. Mita, M. Naito, A. Kasahara, H. Fusamoto, and T. Kamada. 1993. Quantitation of hepatitis C virus RNA in serum of asymptomatic blood donors and patients with type C chronic liver disease. Hepatology 17:545-550.
22. Hashimoto, M., K. Chayama, M. Kobayashi, A. Tsubota, Y. Arase, S. Saitoh, Y. Suzuki, K. Ikeda, M. Matsuda, H. Koike, M. Kobayashi, H. Handa, and H. Kumada. 1999. Fluctuations of hepatitis C virus load are not related to amino acid substitutions in hypervariable region 1 and interferon sensitivity determining region. J. Med. Virol. 58:247-255.
23. Haydon, G. H., L. M. Jarvis, C. S. Blair, P. Simmonds, D. J. Harrison, K. J. Simpson, and P. C. Hayes. 1998. Clinical significance of intrahepatic hepatitis C virus levels in patients with chronic HCV infection. Gut 42:570-575.
24. Heathcote, E. J., M. L. Shiffman, W. G. Cooksley, G. M. Dusheiko, S. S. Lee, L. Balart, R. Reindollar, R. K. Reddy, T. L. Wright, A. Lin, J. Hoffman, and J. De Pamphilis. 2000. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N. Engl. J. Med. 343:1673-1680.
25. Hellier, S., A. J. Frodsham, B. J. W. Hennig, P. Klenerman, S. Knapp, P. Ramaley, J. Satsangi, M. Wright, L. Zhang, H. C. Thomas, M. Thursz, and A. V. Hill. 2003. Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. Hepatology 38:1468-1476.
26. Hennig, B. J. W., S. Hellier, A. J. Frodsham, L. Zhang, P. Klenerman, S. Knapp, M. Wright, H. C. Thomas, M. Thursz, and A. V. Hill. 2002. Association of low-density lipoprotein receptor polymorphisms and outcome of hepatitis C infection. Genes Immun. 3:359-367.
27. Hézode, C., C. Cazeneuve, O. Coué, F. Roudot-Thoraval, I. Lonjon, A. Bastie, C. Duvoux, J.-M. Pawlotsky, E. S. Zafrani, S. Amselem, and D. Dhumeaux. 1999. Liver iron accumulation in patients with chronic active hepatitis C: prevalence and role of hemochromatosis gene mutations and relationship with hepatic histological lesions. J. Hepatol. 31:979-984.
28. Hölder, T., A. Kruger, G. Gerken, P. M. Schneider, K. H. Meyer zum Büschenfelde, and C. Rittner. 1998. Tumor necrosis factor alpha promoter polymorphism at position -238 is associated with chronic active hepatitis C infection. J. Med. Virol. 54:173-177.
29. Jeffers, L. J., W. Cassidy, C. D. Howell, S. Hu, and K. R. Reddy. 2004. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 39:1702-1708.
30. Kazemi-Shirazi, L., C. Datz, T. Maier-Dobersberger, K. Kaserer, F. Hackl, C. Polli, P. E. Steindl, E. Penner, and P. Ferenci. 1999. The relation of iron status and hemochromatosis gene mutations in patients with chronic hepatitis C. Gastroenterology 116:127-134.
31. Knapp, S., B. J. Hennig, A. J. Frodsham, L. Zhang, S. Hellier, M. Wright, R. Goldin, A. V. Hill, H. C. Thomas, and M. R. Thursz. 2003. Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection. Immunogenetics 55:362-369.
32. Knapp, S., L. J. Yee, A. J. Frodsham, B. J. Hennig, S. Hellier, L. Zhang, M. Wright, M. Chiaramonte, M. Graves, H. C. Thomas, A. V. Hill, and M. R. Thursz. 2003. Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. Genes Immun. 4:411-419.
33. Knodell, R. G., K. G. Ishak, W. C. Black, T. S. Chen, R. Craig, N. Kaplowitz, T. W. Kiernan, and J. Wollman. 1981. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1:431-435.
34. Kuramoto, I. K., T. Moriya, V. Schoening, and P. V. Holland. 2002. Fluctuation of serum HCV-RNA levels in untreated blood donors with chronic hepatitis C virus infection. J. Viral. Hepat. 9:36-42.
35. Laperche, S., F. Lunel, J. Izopet, S. Alain, P. Deny, G. Duverlie, C. Gaudy, J.-M. Pawlotsky, J. C. Plantier, B. Pozzetto, V. Thibault, F. Tosetti, and J. J. Lefrere. 2005. Comparison of hepatitis C virus NS5b and 5′ noncoding gene sequencing methods in a multicenter study. J. Clin. Microbiol. 43:733-739.
36. Lindsay, K. L., C. Trepo, T. Heintges, M. L. Shiffman, S. C. Gordon, J. C. Hoefs, E. R. Schiff, Z. D. Goodman, M. Laughlin, R. Yao, and J. K. Albrecht for the Hepatitis Interventional Therapy Group. 2001. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 34:395-403.
37. Manns, M. P., J. G. McHutchison, S. C. Gordon, V. K. Rustgi, M. Shiffman, R. Reindollar, Z. D. Goodman, K. Koury, M. H. Ling, J. K. Albrecht, and the International Hepatitis Interventional Therapy Group. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958-965.
38. Mao, Q., S. C. Ray, O. Laeyendecker, J. R. Ticehurst, S. A. Strathdee, D. Vlahov, and D. L. Thomas. 2001. Human immunodeficiency virus seroconversion and evolution of the hepatitis C virus quasispecies. J. Virol. 75:3259-3267.
39. Martinot-Peignoux, M., N. Boyer, D. Cazals-Hatem, B.-N. Pham, A. Gervais, V. Le Breton, S. Levy, C. Degott, D.-C. Valla, and P. Marcellin. 2001. Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA. Hepatology 34:1000-1005.
40. Mason, A. L., J. Y. Lau, N. Hoang, K. Qian, G. J. Alexander, L. Xu, L. Guo, S. Jacob, F. G. Regenstein, R. Zimmerman, J. E. Everhart, C. Wasserfall, N. K. Maclaren, and R. P. Perrillo. 1999. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 29:328-333.
41. McHutchison, J. G., S. C. Gordon, E. R. Schiff, M. L. Shiffman, W. M. Lee, V. K. Rustgi, Z. D. Goodman, M.-H. Ling, S. Cort, and J. K. Albrecht for the Hepatitis Interventional Therapy Group. 1998. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 339:1485-1492.
42. Morishima, C., S. J. Polyak, R. Ray, M. C. Doherty, A. M. Di Bisceglie, P. F. Malet, H. L. Bonkovsky, D. G. Sullivan, D. R. Gretch, A. L. Rothman, M. J. Koziel, K. L. Lindsay, and Hepatitis C Antiviral Long-Term Treatment against Cirrhosis Trial Group. 2006. Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with non-response to antiviral therapy during advanced hepatitis C. J. Infect. Dis. 193:931-940.
43. Negro, F., K. Krawczynski, R. Quadri, L. Rubbia-Brandt, M. Mondelli, J. P. Zarski, and A. Hadengue. 1999. Detection of genomic- and minus-strand of hepatitis C virus RNA in the liver of chronic hepatitis C patients by strand-specific semiquantitative reverse-transcriptase polymerase chain reaction. Hepatology 29:536-542.
44. Nguyen, T. T., A. Sedghi-Vaziri, L. B. Wilkes, T. Mondala, P. J. Pockros, K. L. Lindsay, and J. G. McHutchison. 1996. Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection. J. Viral Hepat. 3:75-78.
45. Nolte, F. S., A. M. Green, K. R. Fiebelkorn, A. M. Caliendo, C. Sturchio, A. Grunwald, and M. Healy. 2003. Clinical evaluation of two methods for genotyping hepatitis C virus based on analysis of the 5′ noncoding region. J. Clin. Microbiol. 41:1558-1564.
46. Pawlotsky, J.-M. 2002. Use and interpretation of virological tests for hepatitis C. Hepatology 36:S65-S73.
47. Pawlotsky, J.-M., M. Bouvier-Alias, C. Hézode, F. Darthuy, J. Remire, and D. Dhumeaux. 2000. Standardization of hepatitis C virus RNA quantification. Hepatology 32:654-659.
48. Pockros, P. J., R. Carithers, P. Desmond, D. Dhumeaux, M. W. Fried, P. Marcellin, M. L. Shiffman, G. Minuk, K. R. Reddy, R. W. Reindollar, A. Lin, and M. J. Brunda for the Pegasys® International Study Group. 2004. Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial. Am. J. Gastroenterol. 99:1298-1305.
49. Pontisso, P., G. Bellati, M. Brunetto, L. Chemello, G. Colloredo, R. Di Stefano, M. Nicoletti, M. G. Rumi, M. G. Ruvoletto, R. Soffredini, L. M. Valenza, and G. Colucci. 1999. Hepatitis C virus RNA profiles in chronically infected individuals: do they relate to disease activity? Hepatology 29:585-589.
50. Powell, E. E., C. J. Edwards-Smith, J. L. Hay, A. D. Clouston, D. H. Crawford, C. Shorthouse, D. M. Purdie, and J. R. Jonsson. 2000. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 31:828-833.
51. Poynard, T., P. Marcellin, S. S. Lee, C. Niederau, G. S. Minuk, G. Ideo, V. Bain, J. Heathcote, S. Zeuzem, C. Trepo, and J. Albrecht for the International Hepatitis Interventional Therapy Group (IHIT). 1998. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352:1426-1432.
52. Prati, D., M. L. Shiffman, M. Diago, E. Gane, K. R. Reddy, P. Pockros, P. Farci, C. B. O'Brien, P. Lardelli, S. Blotner, and S. Zeuzem. 2006. Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C. J. Hepatol. 44:679-685.
53. Rai, R., L. E. Wilson, J. Astemborski, F. Anania, M. Torbenson, C. Spoler, D. Vlahov, S. A. Strathdee, J. Boitnott, K. E. Nelson, and D. L. Thomas. 2002. Severity and correlates of liver disease in hepatitis C virus-infected injection drug users. Hepatology 35:1247-1255.
54. Reddy, K. R., T. L. Wright, P. J. Pockros, M. Shiffman, G. Everson, R. Reindollar, M. W. Fried, P. P. Purdum, D. Jensen, C. Smith, W. M. Lee, T. D. Boyer, A. Lin, S. Pedder, and J. De Pamphilis. 2001. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 33:433-438.
55. Rothman, A. L., C. Morishima, H. L. Bonkovsky, S. J. Polyak, R. Ray, A. M. Di Bisceglie, K. L. Lindsay, P. F. Malet, M. Chang, D. R. Gretch, D. G. Sullivan, A. K. Bhan, E. C. Wright, and M. J. Koziel. 2005. Associations among clinical, immunological, and viral quasispecies measurements in advanced chronic hepatitis C. Hepatology 41:617-625.
56. Sherman, K. E., J. O'Brien, A. G. Gutierrez, S. Harrison, M. Urdea, P. Neuwald, and J. Wilber. 1993. Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infections. J. Clin. Microbiol. 31:2679-2682.
57. Smith, B. C., J. Grove, M. A. Guzail, C. P. Day, A. K. Daly, A. D. Burt, and M. F. Bassendine. 1998. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology 27:1695-1699.
58. Smith, D. B., J. Mellor, L. M. Jarvis, F. Davidson, J. Kolberg, M. Urdea, P. L. Yap, P. Simmonds, et al. 1995. Variation of the hepatitis C virus 5′ non-coding region: implications for secondary structure, virus detection and typing. J. Gen. Virol. 76:1749-1761.
59. Strasfeld, L., Y. Lo, D. Netski, D. L. Thomas, and R. S. Klein. 2003. The association of hepatitis C prevalence, activity, and genotype with HIV infection in a cohort of New York City drug users. J. Acquir. Immune. Defic. Syndr. 33:356-364.
60. Thio, C. L., X. Gao, J. J. Goedert, D. Vlahov, K. E. Nelson, M. W. Hilgartner, S. J. O'Brien, P. Karacki, J. Astemborski, M. Carrington, and D. L. Thomas. 2002. HLA-Cw*04 and hepatitis C virus persistence. J. Virol. 76:4792-4797.
61. Thio, C. L., D. L. Thomas, and M. Carrington. 2000. Chronic viral hepatitis and the human genome. Hepatology 31:819-827.
62. Thio, C. L., D. L. Thomas, J. J. Goedert, D. Vlahov, K. E. Nelson, M. W. Hilgartner, S. J. O'Brien, P. Karacki, D. Marti, J. Astemborski, and M. Carrington. 2001. Racial differences in HLA class II associations with hepatitis C virus outcomes. J. Infect. Dis. 184:16-21.
63. Thomas, D. L., J. Astemborski, D. Vlahov, S. A. Strathdee, S. C. Ray, K. E. Nelson, N. Galai, K. R. Nolt, O. Laeyendecker, and J. A. Todd. 2000. Determinants of the quantity of hepatitis C virus RNA. J. Infect. Dis. 181:844-851.
64. Thomas, D. L., J. Astemborski, R. M. Rai, F. A. Anania, M. Schaeffer, N. Galai, K. Nolt, K. E. Nelson, S. A. Strathdee, L. Johnson, O. Laeyendecker, J. Boitnott, L. E. Wilson, and D. Vlahov. 2000. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 284:450-456.
65. Thomas, D. L., J. D. Rich, P. Schuman, D. K. Smith, J. A. Astemborski, K. R. Nolt, and R. S. Klein for the HIV Epidemiology Research (HER) Study Group. 2001. Multicenter evaluation of hepatitis C RNA levels among female injection drug users. J. Infect. Dis. 183:973-976.
66. Thomas, D. L., J. W. Shih, H. J. Alter, D. Vlahov, S. Cohn, D. R. Hoover, L. Cheung, and K. E. Nelson. 1996. Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J. Infect. Dis. 174: 690-695.
67. Thursz, M. 2001. MHC and the viral hepatitides. Q. J. Med. 94:287-291. (Editorial.)
68. Wilson, L. E., M. Torbenson, J. Astemborski, H. Faraki, C. Spoler, R. Rai, S. Mehta, G. D. Kirk, K. Nelson, N. Afdhal, and D. L. Thomas. 2006. Progression of liver fibrosis among injection drug users with chronic hepatitis C. Hepatology 43:788-795.
69. Wright, M., R. Goldin, S. Hellier, S. Knapp, A. Frodsham, B. Hennig, A. Hill, R. Apple, S. Cheng, H. Thomas, and M. Thursz. 2003. Factor V Leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection. Gut 52:1206-1210.
70. Yeo, A. E. T., M. Ghany, C. Conry-Cantilena, J. C. Melpolder, D. E. Kleiner, J. W. K. Shih, J. H. Hoofnagle, and H. J. Alter. 2001. Stability of HCV-RNA level and its lack of correlation with disease severity in asymptomatic chronic hepatitis C virus carriers. J. Viral Hepat. 8:256-263.
71. Zein, N. N. 2000. Clinical significance of hepatitis C virus genotypes. Clin. Microbiol. Rev. 13:223-235.
72. Zeuzem, S., S. V. Feinman, J. Rasenack, E. J. Heathcote, M. Y. Lai, E. Gane, J. O'Grady, J. Reichen, M. Diago, A. Lin, J. Hoffman, and M. J. Brunda. 2000. Peginterferon alfa-2a in patients with chronic hepatitis C. N. Engl. J. Med. 343:1666-1672.